Dayvigo vs Trazodone: Head-to-Head Efficacy for Insomnia

Why No Direct Head-to-Head Trial Exists

Lemborexant and trazodone belong to entirely different pharmacological classes, and their regulatory histories diverge sharply. Eisai developed lemborexant through a full FDA new drug application pathway with two Phase III insomnia trials [1][3]. Trazodone, first approved as an antidepressant in 1981, drifted into insomnia use without any manufacturer-sponsored key sleep trial [4]. The absence of a patent incentive means no company has funded the head-to-head comparison clinicians need.

A 2017 systematic review in the Journal of Clinical Sleep Medicine identified only five randomized trials examining trazodone specifically for insomnia, and none lasted longer than two weeks [5]. By contrast, SUNRISE-2 tracked lemborexant outcomes over 12 months in 949 adults with insomnia disorder [3]. The data asymmetry makes cross-trial comparison imperfect but necessary for clinical decision-making. The American Academy of Sleep Medicine (AASM) 2023 guidelines conditionally recommend dual orexin receptor antagonists (DORAs) for chronic insomnia and explicitly note insufficient evidence to recommend trazodone [6].

Lemborexant Efficacy: What SUNRISE-1 and SUNRISE-2 Show

SUNRISE-1 (N=1,006) was a randomized, double-blind, placebo- and active-comparator-controlled trial in adults aged 55 and older with insomnia disorder [1]. Participants received lemborexant 5 mg, lemborexant 10 mg, zolpidem extended-release 6.25 mg, or placebo. The primary endpoint was change from baseline in latency to persistent sleep (LPS) measured by polysomnography at one month.

Lemborexant 5 mg reduced LPS by 10.7 minutes more than placebo (P<0.001), and lemborexant 10 mg reduced it by 12.6 minutes more than placebo (P<0.001) [1]. Both doses also improved sleep efficiency and wake after sleep onset (WASO). Lemborexant 10 mg reduced WASO by 20.2 minutes versus placebo, a clinically meaningful difference for patients with frequent nighttime awakenings [1].

SUNRISE-2, the long-term extension study, demonstrated sustained efficacy over six months with no evidence of tolerance development [3]. Subjective sleep onset latency (sSOL) decreased by approximately 23 minutes from baseline at month six with lemborexant 10 mg [3]. Rebound insomnia after discontinuation was not significantly different from placebo, a distinction from some benzodiazepine receptor agonists [7].

The FDA label for Dayvigo lists somnolence (the most common adverse event at 10% for the 10 mg dose vs 1% placebo) and sleep paralysis (uncommon at approximately 1%) as key safety signals [8]. Complex sleep behaviors including sleepwalking prompted a class-wide DORA boxed warning in 2020 [8].

Trazodone Efficacy: What the Limited Data Show

Trazodone's insomnia evidence rests on a thin clinical foundation. The Mendelson 2005 trial (N=306) randomized patients with primary insomnia to trazodone 50 mg, zolpidem 10 mg, or placebo for two weeks [2]. Trazodone reduced subjective sleep latency during the first week but showed no statistically significant separation from placebo by week two on the primary endpoint [2].

A smaller crossover study by Walsh et al. (N=60) found that trazodone 50 mg improved polysomnographic sleep efficiency during the first week but not at the two-week mark [9]. These results suggest acute but potentially non-durable benefits. A 2023 meta-analysis published in Sleep Medicine Reviews confirmed trazodone modestly improves subjective sleep quality in the short term (standardized mean difference 0.34 to 95% CI 0.12 to 0.57) but noted high heterogeneity and a lack of trials beyond 14 days [10].

Despite this evidence gap, trazodone remains the second most commonly prescribed medication for insomnia in U.S. clinical practice. Data from a 2019 JAMA Internal Medicine cross-sectional study showed trazodone accounted for nearly 21 million insomnia-related prescriptions annually in the United States [11]. Clinicians frequently choose it because of its low cost, low abuse potential, and absence of DEA scheduling.

Cross-Trial Efficacy Comparison

Direct numerical comparison requires caution because SUNRISE-1 and Mendelson 2005 used different patient populations, endpoints, and assessment tools. With that caveat, the available numbers paint a clear picture.

For sleep onset, lemborexant 5 mg achieved a placebo-adjusted reduction in objective LPS of 10.7 minutes at 30 days in SUNRISE-1 [1]. Trazodone 50 mg achieved approximately 10 minutes of placebo-adjusted reduction in subjective sleep latency, but only during week one in Mendelson 2005, with the effect gone by week two [2]. For sleep maintenance, lemborexant 10 mg reduced WASO by 20.2 minutes versus placebo at day 30 [1]. No trazodone trial has reported a statistically significant WASO improvement beyond one week [10].

Long-term data further separate the two agents. SUNRISE-2 provided six-month durability evidence for lemborexant [3]. No trazodone randomized trial has extended past 14 days. The AASM 2023 practice guideline gave DORAs a conditional recommendation (moderate-quality evidence) and stated there is "insufficient evidence to recommend for or against trazodone" for chronic insomnia [6].

Mechanism of Action: How Each Drug Promotes Sleep

Lemborexant is a dual orexin receptor antagonist (DORA). It blocks the wake-promoting neuropeptides orexin-A and orexin-B at both OX1R and OX2R receptors [12]. This reduces wakefulness rather than inducing sedation, preserving more normal sleep architecture. Polysomnography from SUNRISE-1 confirmed lemborexant increased REM sleep percentage, a marker of physiological sleep quality [1].

Trazodone works through a different pathway. At doses of 25 to 100 mg (far below antidepressant doses of 150 to 400 mg), its sedative effect comes primarily from antagonism at histamine H1 receptors and serotonin 5-HT2A receptors [13]. It also weakly blocks alpha-1 adrenergic receptors, which contributes to orthostatic hypotension. Unlike DORAs, trazodone at hypnotic doses may suppress REM sleep, though this effect is inconsistent across small studies [13].

The pharmacokinetic profiles differ meaningfully for patients concerned about morning hangover. Lemborexant has a half-life of approximately 17 to 19 hours, yet SUNRISE-1 showed no significant next-morning psychomotor impairment at the 5 mg dose compared to placebo on the digit symbol substitution test [1]. Trazodone's half-life ranges from 5 to 9 hours, but its active metabolite meta-chlorophenylpiperazine (mCPP) can cause next-day grogginess and headaches in some patients [14].

Side Effect Profiles Compared

Lemborexant's most frequently reported adverse events in SUNRISE-1 and SUNRISE-2 include somnolence (7% at 5 mg, 10% at 10 mg), headache (6%), and abnormal dreams (2% to 3%) [1][8]. Sleep paralysis occurred in roughly 1% of patients on lemborexant 10 mg [8]. The 2020 FDA class-wide DORA warning for complex sleep behaviors (sleepwalking, sleep-driving) applies to all three marketed DORAs: suvorexant, lemborexant, and daridorexant [15].

Trazodone's side effect profile at low doses includes morning sedation, dry mouth, dizziness, and orthostatic hypotension [14]. Priapism is rare (estimated at 1 in 6,000 to 8,000 male patients) but constitutes a urological emergency [14]. Trazodone carries a boxed warning for increased suicidality in patients under 25, inherited from its antidepressant class labeling [4]. Cardiac QT prolongation has been reported at higher antidepressant doses but is considered minimal risk at 50 mg insomnia doses [14].

A 2020 Veterans Affairs retrospective cohort study (N=189,467) found that trazodone use for insomnia was associated with a lower rate of falls compared to zolpidem (adjusted HR 0.85 to 95% CI 0.80 to 0.90), suggesting a favorable safety profile relative to Z-drugs in older adults [16]. Lemborexant has not yet been compared to trazodone in fall-risk analyses.

Cost and Access Considerations

The pricing gap between these medications is substantial. Brand-name Dayvigo costs approximately $400 to $500 per month without insurance [8]. No generic lemborexant is currently available in the United States. Eisai's patent protection extends to at least 2032. Manufacturer copay assistance programs can reduce the out-of-pocket cost to as low as $30 per month for commercially insured patients [8].

Generic trazodone costs between $4 and $15 per month at most pharmacies [4]. It appears on the $4 generic lists at major retailers. Because trazodone is not a controlled substance, refills and prior authorizations are simpler. Lemborexant is a Schedule IV controlled substance, requiring a new prescription or authorized refills [8].

Insurance formulary placement varies. Many commercial plans and Medicare Part D formularies cover lemborexant with a prior authorization requiring documentation of failed first-line therapy (typically cognitive behavioral therapy for insomnia, or CBT-I, plus one alternative medication) [8]. Trazodone, by contrast, rarely requires prior authorization for insomnia use despite its off-label status [4].

Who Might Benefit From Each Medication

Lemborexant may be a better fit for patients who need documented long-term efficacy data, those with sleep maintenance insomnia (based on the WASO improvements in SUNRISE-1), and patients who have tried and failed trazodone or Z-drugs [1][6]. Its mechanism preserves closer-to-normal sleep architecture, which may matter for patients who report feeling unrested despite adequate total sleep time.

Trazodone may be preferable for patients with comorbid depression and insomnia (since it addresses both conditions), those on a limited budget, and patients who want to avoid a controlled substance [13]. Its extensive real-world use over four decades gives clinicians familiarity with its safety profile, even if rigorous trial data remain limited [10][11].

Both the AASM and the American College of Physicians recommend CBT-I as first-line insomnia therapy, with pharmacotherapy reserved for patients who do not respond adequately [6][17]. Prescribers should discuss CBT-I before or alongside either medication.

Switching Between Dayvigo and Trazodone

No published protocol governs switching from lemborexant to trazodone or vice versa. Because these drugs act on entirely different receptor systems, there is no pharmacological cross-tolerance. In clinical practice, the transition is typically straightforward: stop one agent at bedtime and start the other the following night.

Patients switching from trazodone to lemborexant should be aware of the controlled-substance scheduling, which may affect refill logistics [8]. Patients moving from lemborexant to trazodone should be counseled about orthostatic hypotension risk, particularly if they are older or on antihypertensive medications [14]. No taper is required for either drug at insomnia doses, though clinicians may choose a brief overlap period for patients with severe insomnia to avoid rebound wakefulness.